Myasthenia Gravis Treatment Market Report 2026

Myasthenia Gravis Treatment Market Overview

• Myasthenia Gravis Treatment market size has reached to $1.66 billion in 2025 • Expected to grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Myasthenia Gravis Treatment Market Surges In Response To Escalating Disease Prevalence • Market Trend: Product Innovations Drive Growth In Myasthenia Gravis Treatment Market With FDA Approval Of Zilucoplan • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Myasthenia Gravis Treatment Market?

Myasthenia gravis treatment refers to the process of providing health care services by health care providers and taking care of a patient to combat myasthenia gravis, an autoimmune neuromuscular disease causing fatigue and weakness in the skeletal muscles. The main treatments for myasthenia gravis are medication, surgery, and others. Medication refers to medicine or drugs that are used to improve a particular illness, such as myasthenia gravis. Pyridostigmine is a commonly used medication for myasthenia that helps electrical signals travel between the nerves and muscles. The myasthenia gravis treatment uses various medication types such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others and is used by hospitals, clinics, and others.

What Is The Myasthenia Gravis Treatment Market Growth Forecast?

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growth in monoclonal antibody development, increasing demand for minimally invasive surgery, expansion of specialty clinics, rising use of ivig and advanced immunotherapies, enhanced diagnostic capabilities through ai-based tools. Major trends in the forecast period include rising adoption of immunosuppressive therapies, growing use of monoclonal antibodies for mg treatment, increasing preference for minimally invasive thymectomy, higher demand for ivig and plasmapheresis in severe cases, expansion of supportive and combination therapy approaches.

Global Myasthenia Gravis Treatment Market Segmentation

1) By Treatment: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Plasmapheresis Or Intravenous Immunoglobulin (IVIg), Thymectomy Or Surgical Options, Other Treatments 2) By Route Of Administration: Oral, Intravenous, Subcutaneous 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Or E-commerce 4) By End User: Hospitals, Clinics, Other End-Users Subsegments: 1) By Anticholinesterase Agents: Pyridostigmine, Neostigmine, Ambenonium 2) By Immunosuppressants: Corticosteroids, Azathioprine, Mycophenolate Mofetil, Cyclosporine, Tacrolimus 3) By Monoclonal Antibodies: Eculizumab, Rituximab 4) By Plasmapheresis Or Intravenous Immunoglobulin (IVIg): Plasma Exchange Therapy, IVIg Infusions 5) By Thymectomy Or Surgical Options: Transsternal Thymectomy, Minimally Invasive Thymectomy, Robot-Assisted Thymectomy 6) By Other Treatments: Symptomatic Therapy, Complement Inhibitors, Experimental Therapies

What Is The Driver Of The Myasthenia Gravis Treatment Market?

The surge in the prevalence of myasthenia gravis is expected to propel the growth of the myasthenia gravis treatment market going forward. Myasthenia gravis refers to an autoimmune neuromuscular disease condition in which patients experience fatigue and weakness in the skeletal muscles. Myasthenia gravis treatment is the process of providing health care services and taking care of a patient to combat myasthenia gravis. Thus, the surge in the prevalence of myasthenia gravis is boosting sales in the myasthenia gravis treatment market. For instance, in January 2024, according to the Myaware, a UK-based charity, based on a United Kingdom population of approximately 67,817,100, an estimated 22,855 individuals are currently living with myasthenia gravis, 204 with Lambert-Eaton myasthenic syndrome, and 2,103 with congenital myopathies. Therefore, the surge in the prevalence of myasthenia gravis is driving the growth of the myasthenia gravis treatment industry.

Key Players In The Global Myasthenia Gravis Treatment Market

Major companies operating in the myasthenia gravis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Argenx SE, Immunovant Inc., Cabaletta Bio Inc., RemeGen Co. Ltd., Kedrion SpA

Global Myasthenia Gravis Treatment Market Trends and Insights

Major companies operating in the myasthenia gravis treatment market are focusing on developing innovative products such as self-administered complement C5 inhibitors to improve treatment convenience, enhance patient autonomy, and reduce reliance on infusion-based care. Self-administered complement C5 inhibitors refer to targeted autoimmune therapies formulated for subcutaneous use, enabling patients to control excessive complement activation while administering treatment independently at home rather than in clinical infusion settings. For instance, in October 2023, UCB Pharma, a Belgium-based pharmaceutical company, announced the US Food and Drug Administration (FDA) approved Zilucoplan. It is used for treating adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. This approval introduces a new option in the management of gMG, which is characterized by muscle weakness due to an autoimmune response. ZILBRYSQ is notable for being a self-administered, once-daily subcutaneous complement C5 inhibitor. This provides a convenient alternative to traditional intravenous therapies that have been the standard for treating gMG.

What Are Latest Mergers And Acquisitions In The Myasthenia Gravis Treatment Market?

In November 2023, Selecta Biosciences, Inc. a US-based biotechnology company merger with Cartesian Therapeutics for an undisclosed amount. The merger strengthens Selecta's commitment to RNA cell therapies for autoimmune diseases, specifically myasthenia gravis (MG). It seeks to utilize Cartesian's cutting-edge RNA-engineering platform and pipeline, which features the promising rCAR-T therapy Descartes-08, to expedite development and deliver effective treatment solutions. Cartesian Therapeutics is a US-based biotechnology company that develops potential treatments for generalized myasthenia gravis.

Regional Outlook

North America was the largest region in the myasthenia gravis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Myasthenia Gravis Treatment Market?

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Myasthenia Gravis Treatment Market Report 2026?

The myasthenia gravis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.